

FAQ

FREQUENTLY-ASKED MIFID II AND PRIIPS QUESTIONS

MiFID was applied in the UK from November 2007, but is now being revised to improve the functioning of financial markets. The changes take effect from 3 January 2018, with the new legislation being known as MiFID II—this includes a revised MiFID and a new Markets in Financial Instruments Regulation (MiFIR). You can find more information about MiFID II on the [FCA website here](#).

The aim of the [PRIIPs Regulation](#), which takes effect from 1 January 2018, is to encourage efficient EU markets by helping investors to better understand and compare the key features, risk, rewards and costs of different PRIIPs, through access to a short and consumer-friendly Key Information Document (or KID).

Please note the subtle difference between the UCITS **KIID** (Key Investor Information Document) and the PRIIPs **KID** (Key Information Document), below.

1. Will you produce KIDs for the WisdomTree UCITS ETF products for 1 January 2018?	<p>No. Under the new PRIIPs regulatory guidelines, we are not required to produce KIDs for our UCITS ETFs until 31 December 2019.</p> <p>We will, however, continue to use the KIIDs which are available in a wide range of European languages, on our website, by clicking here.</p> <p>The KIIDs are also available under the Information and Research box on all of our UCITS ETF product pages, as can be seen for example on the DEMA product page.</p>
2. Will you produce KIDs for the Boost ETP product range for 1 January 2018, and if so, where can I find them?	<p>Yes. These are now available on our website on the Prospectus and Regulatory section.</p>
3. Which languages will the Boost ETP KIDs be in?	<p>Our Boost ETP KIDs are offered in English, German and Italian.</p>
4. Would WisdomTree upload your KIDs to my FTP server for me?	<p>Regretfully we are currently not able to offer this service, however all of our regulatory documents have been distributed to some major data providers, (for example, Financial Express, Fundinfo, FundsLibrary and Morningstar).</p>
5. Are you producing the European MiFID Template (EMT) file for your UCITS ETFs and Boost ETPs?	<p>Yes, you can download the EMT excel file, available in English only, here on the MiFID II tab.</p>
6. Are you producing the European PRIIPs Template (EPT) file for your Boost ETPs?	<p>Yes, you can download the EPT excel file here on the PRIIPs tab.</p>
7. Will MiFID II affect the WisdomTree US 40 Act ETFs offered in the US?	<p>No, as the WisdomTree US 40 Act ETFs are distributed in the US only.</p>
8. Which data providers are able to provide WisdomTree regulatory documents, such as EMTs and KIDs, to my clients?	<p>All of our regulatory documents have been distributed to some major data providers (for example, Financial Express, Fundinfo, FundsLibrary and Morningstar).</p>



<p>9. Will I be charged for WisdomTree’s research?</p>	<p>No. It is WisdomTree Europe’s policy that any research will be made freely available via its website.</p> <p>It is not intended that any blogs, articles, whitepapers and research, whether distributed via email, social media, advertising or any other method, will fall into the payable research category under MiFID II.</p> <p>All of the content we produce is generic, does not include a “sell/buy/hold” indication for any investment and is publicly available and viewable via our website and the email newsletter if you are registered to receive it.</p> <p>You will not and will never be charged for WisdomTree’s content.</p>
<p>10. How do I remove me/my client/someone from my company/my company from your distribution list?</p>	<p>If WisdomTree’s content is currently not of interest to you, we are able to remove you from our distribution list.</p> <p>Kindly note that should you change your mind in the future, you can again opt in to receive our e-newsletter and you will not be charged for the content provided, as all of our research is available on our website at www.wisdomtree.eu.</p>
<p>11. Where do I find ongoing costs?</p>	<p>The costs and ongoing costs disclosure for all WisdomTree UCITS ETFs and Boost ETPs are set out in the EMT, here on the MiFID II tab.</p>
<p>12. You haven’t produced an EMT for your ICBCS WisdomTree S&P China 500 UCITS ETF. Will you be producing one soon?</p>	<p>Yes. We are finalising documentation for this ETF and it should be available by January 22nd. This will be updated on our website then.</p>
<p>13. Do WisdomTree events, blogs and brochures qualify as “investment research”?</p>	<p>No. All our content—whether it is provided in a blog, brochure, presentation or event format – qualify as marketing communications, as provided under MiFID II level 2 guidance in Article 36 of the Commission Delegated Regulation (EU) 2017/565 of 25.4.2016, and therefore, it is neither an inducement nor is it chargeable.</p>



IMPORTANT INFORMATION

Communications issued in the European Economic Area (“EEA”): This document has been issued and approved by WisdomTree Ireland Limited, which is authorised and regulated by the Central Bank of Ireland.

Communications issued in jurisdictions outside of the EEA: This document has been issued and approved by WisdomTree UK Limited, which is authorised and regulated by the United Kingdom Financial Conduct Authority.

WisdomTree Ireland Limited and WisdomTree UK Limited are each referred to as “WisdomTree” (as applicable). Our Conflicts of Interest Policy and Inventory are available on request.

For professional clients only. Past performance is not a reliable indicator of future performance. Any historical performance included in this document may be based on back testing. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of such strategy would have been. Back tested performance is purely hypothetical and is provided in this document solely for informational purposes. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance. The value of any investment may be affected by exchange rate movements. Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice. These products may not be available in your market or suitable for you. The content of this document does not constitute investment advice nor an offer for sale nor a solicitation of an offer to buy any product or make any investment.

An investment in exchange-traded products (“ETPs”) is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely. ETPs involve numerous risks including among others, general market risks relating to the relevant underlying index, credit risks on the provider of index swaps utilised in the ETP, exchange rate risks, interest rate risks, inflationary risks, liquidity risks and legal and regulatory risks.

The information contained in this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares in the United States or any province or territory thereof, where none of the issuers or their products are authorised or registered for distribution and where no prospectus of any of the issuers has been filed with any securities commission or regulatory authority. No document or information in this document should be taken, transmitted or distributed (directly or indirectly) into the United States. None of the issuers, nor any securities issued by them, have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes.

This document may contain independent market commentary prepared by WisdomTree based on publicly available information. Although WisdomTree endeavours to ensure the accuracy of the content in this document, WisdomTree does not warrant or guarantee its accuracy or correctness. Any third party data providers used to source the information in this document make no warranties or representation of any kind relating to such data. Where WisdomTree has expressed its own opinions related to product or market activity, these views may change. Neither WisdomTree, nor any affiliate, nor any of their respective officers, directors, partners, or employees accepts any liability whatsoever for any direct or consequential loss arising from any use of this document or its contents.

This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes and/or sectors. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could differ materially from those anticipated in such statements. WisdomTree strongly recommends that you do not place undue reliance on these forward-looking statements.



WisdomTree Issuer PLC

The products discussed in this document are issued by WisdomTree Issuer PLC ("WT Issuer"). WT Issuer is an umbrella investment company with variable capital having segregated liability between its funds organised under the laws of Ireland as a public limited company and authorised by the Central Bank of Ireland ("CBI"). WT Issuer is organised as an Undertaking for Collective Investment in Transferable Securities ("UCITS") under the laws of Ireland and shall issue a separate class of shares ("Shares") representing each fund. Investors should read the prospectus of WT Issuer ("WT Prospectus") before investing and should refer to the section of the WT Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in the Shares.

Boost Issuer PLC

Boost Issuer PLC (the "Issuer") issues products under a Prospectus ("Boost Prospectus") approved by the Central Bank of Ireland, drawn up in accordance with the Directive 2003/71/EC. The Boost Prospectus has been passported to various European jurisdictions including the UK, Italy and Germany and is available on this document.

Notice to Investors in Switzerland – Qualified Investors: Some of the sub-funds referred to in this document may not have not been registered with the Swiss Financial Market Supervisory Authority ("FINMA"). In Switzerland, such sub-funds that have not been registered with FINMA shall be distributed exclusively to qualified investors, as defined in the Swiss Federal Act on Collective Investment Schemes or its implementing ordinance (each, as amended from time to time). The representative and paying agent of the sub-funds in Switzerland is Société Générale Paris, Zurich Branch, Talacker 50, PO Box 5070, 8021 Zurich, Switzerland. The prospectus, the key investor information documents (KIID), the articles of association and the annual and semi-annual reports of the sub-funds are available free of charge from the representative and paying agent. As regards distribution in Switzerland, the place of jurisdiction and performance is at the registered seat of the representative and paying agent.

For Investors in France: The information in this document is intended exclusively for professional investors (as defined under the MiFID) investing for their own account and this material may not in any way be distributed to the public. The distribution of the Prospectus and the offering, sale and delivery of Shares in other jurisdictions may be restricted by law. WT Issuer is a UCITS governed by Irish legislation, and approved by the Financial Regulatory as UCITS compliant with European regulations although may not have to comply with the same rules as those applicable to a similar product approved in France. The Fund has been registered for marketing in France by the Financial Markets Authority (Autorité des Marchés Financiers) and may be distributed to investors in France. Copies of all documents (i.e. the Prospectus, the Key Investor Information Document, any supplements or addenda thereto, the latest annual reports and the memorandum of incorporation and articles of association) are available in France, free of charge at the French centralizing agent, Societe Generale at 29, Boulevard Haussmann, 75009, Paris, France. Any subscription for Shares of the Fund will be made on the basis of the terms of the prospectus and any supplements or addenda thereto.

For Investors in Malta: This document does not constitute or form part of any offer or invitation to the public to subscribe for or purchase shares in the Fund and shall not be construed as such and no person other than the person to whom this document has been addressed or delivered shall be eligible to subscribe for or purchase shares in the Fund. Shares in the Fund will not in any event be marketed to the public in Malta without the prior authorisation of the Maltese Financial Services Authority.